A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (NCT05071300)

🧪 Interventions in This Study

• Eplontersen (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (33 Sites)

Showing the first 25 of 33 sites.

• Mayo Clinic — Scottsdale, Arizona
• Indiana University Health University Hospital — Indianapolis, Indiana
• Johns Hopkins University Neurology Research Office — Baltimore, Maryland
• Boston University School of Medicine — Boston, Massachusetts
• The Neurological Institute of New York — New York, New York
• University of North Carolina Hospitals - Neurology Clinic — Chapel Hill, North Carolina
• Oregon Health and Science University — Portland, Oregon
• University of Washington Medical Center — Seattle, Washington
• Hospital Italiano de Buenos Aires — Buenos Aires,
• Instituto Fleni — Buenos Aires,
• Hospital El Cruce — San Juan Bautista,
• Perron Institute for Neurological and Translational Science — Murdoch, Western Australia
• Hospital Universitario Clementino Fraga Filho — Botafogo, Rio de Janeiro
• Universidade Estadual de Campinas — Campinas,
• Instituto de Neurologia de Curitiba — Curitiba,
• Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto — São Paulo,
• Vancouver General Hospital — Vancouver, British Columbia
• Toronto General Hospital — Toronto, Ontario
• The Cyprus Institute of Neurology and Genetics — Égkomi,
• Centre Hospitalier Universitaire de Toulouse — Toulouse, Haute-Garonne
• Hôpital de la Timone — Marseille,
• Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Carlo Besta — Milan,
• Fondazione IRCCS Policlinico San Matteo — Pavia,
• Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria — Lisbon,
• Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio — Porto,

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Hereditary Transthyretin-Mediated Amyloid Polyneuropathy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.